Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

20362

ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg

W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate

Synonym(s):

ORBO™ Carboxen-564 Tube

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
25 ea

Available to ship TODAYfromMILWAUKEE

$211.00

About This Item

EC Number:
231-153-3
UNSPSC Code:
47131900
NACRES:
NB.21

$211.00

Available to ship TODAYDetails

​
Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

material

W,F,F separators

Quality Level

100

agency

NIOSH 1453, OSHA 51

product line

ORBO™

composition

Bed A, 160 mg , Bed B, 80 mg

packaging

pkg of 25 ea

manufacturer/tradename

ORBO™ 92

technique(s)

active air sampling: suitable

O.D. × L

6 mm × 75 mm

matrix

Carboxen® 564 Carbon Molecular Sieve (CMS)

application(s)

air monitoring
environmental
industrial hygiene

compatibility

for analyte group Vinyl acetate

General description

  • ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg solvent desorption tube is designed for gas and vapor sampling.
  • It contains two beds of the same selective adsorbent separated by glass wool or foam.
  • Dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Legal Information

Carboxen is a registered trademark of Merck KGaA, Darmstadt, Germany
ORBO is a trademark of Sigma-Aldrich Co. LLC

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
203582005320042
ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate

Supelco

20362

ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg

Supelco

Supelco

20358

ORBO™ 90 Carboxen® 564 (20/45), 160/80 mg

ORBO™ 615 Amberlite™ XAD®-7 (15/50), 60/30 mg W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea

Supelco

20053

ORBO™ 615 Amberlite™ XAD®-7 (15/50), 60/30 mg

ORBO™ 351 4-TBC on Activated Coconut Charcoal (20/40), 100/50 mg W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea

Supelco

20042

ORBO™ 351 4-TBC on Activated Coconut Charcoal (20/40), 100/50 mg

composition

Bed A, 160 mg , Bed B, 80 mg

composition

Bed A, 160 mg , Bed B, 80 mg

composition

Bed A, 60 mg , Bed B, 30 mg

composition

Bed A, 100 mg , Bed B, 50 mg

material

W,F,F separators

material

W,F,F separators

material

W,W,W separators

material

W,W,W separators

agency

NIOSH 1453, OSHA 51

agency

NIOSH 2500

agency

-

agency

OSHA 56

technique(s)

active air sampling: suitable

technique(s)

active air sampling: suitable

technique(s)

active air sampling: suitable

technique(s)

active air sampling: suitable

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

packaging

pkg of 25 ea

packaging

pkg of 25 ea

packaging

pkg of 50 ea

packaging

pkg of 50 ea

Storage Class

11 - Combustible Solids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
View All Related Papers

Global Trade Item Number

SKUGTIN
2036204061834426257

Questions

Reviews

No rating value

Active Filters